KR20070067189A - 주사제에 유용한 베타-락타마제 억제제를 이용한베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물 - Google Patents

주사제에 유용한 베타-락타마제 억제제를 이용한베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물 Download PDF

Info

Publication number
KR20070067189A
KR20070067189A KR1020077010375A KR20077010375A KR20070067189A KR 20070067189 A KR20070067189 A KR 20070067189A KR 1020077010375 A KR1020077010375 A KR 1020077010375A KR 20077010375 A KR20077010375 A KR 20077010375A KR 20070067189 A KR20070067189 A KR 20070067189A
Authority
KR
South Korea
Prior art keywords
sodium
composition
sulbactam
ceftriaxone
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077010375A
Other languages
English (en)
Korean (ko)
Inventor
마누 챠우드해리
Original Assignee
비너스 레머디스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비너스 레머디스 리미티드 filed Critical 비너스 레머디스 리미티드
Publication of KR20070067189A publication Critical patent/KR20070067189A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
KR1020077010375A 2004-12-02 2005-11-28 주사제에 유용한 베타-락타마제 억제제를 이용한베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물 Ceased KR20070067189A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2411/DEL/2004 2004-12-02
IN2411DE2004 2004-12-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097018388A Division KR101244362B1 (ko) 2004-12-02 2005-11-28 주사제에 유용한 베타-락타마제 억제제를 이용한 베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물

Publications (1)

Publication Number Publication Date
KR20070067189A true KR20070067189A (ko) 2007-06-27

Family

ID=35789266

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077010375A Ceased KR20070067189A (ko) 2004-12-02 2005-11-28 주사제에 유용한 베타-락타마제 억제제를 이용한베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물
KR1020097018388A Expired - Fee Related KR101244362B1 (ko) 2004-12-02 2005-11-28 주사제에 유용한 베타-락타마제 억제제를 이용한 베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097018388A Expired - Fee Related KR101244362B1 (ko) 2004-12-02 2005-11-28 주사제에 유용한 베타-락타마제 억제제를 이용한 베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물

Country Status (23)

Country Link
US (2) US8273732B2 (cg-RX-API-DMAC7.html)
EP (1) EP1841432B1 (cg-RX-API-DMAC7.html)
JP (1) JP5269415B2 (cg-RX-API-DMAC7.html)
KR (2) KR20070067189A (cg-RX-API-DMAC7.html)
CN (1) CN101060846A (cg-RX-API-DMAC7.html)
AT (1) ATE476981T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005310888B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0517128A (cg-RX-API-DMAC7.html)
CY (1) CY1110886T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005022939D1 (cg-RX-API-DMAC7.html)
DK (1) DK1841432T3 (cg-RX-API-DMAC7.html)
ES (1) ES2349301T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100591T1 (cg-RX-API-DMAC7.html)
MX (1) MX2007006540A (cg-RX-API-DMAC7.html)
NZ (1) NZ555075A (cg-RX-API-DMAC7.html)
PL (1) PL1841432T3 (cg-RX-API-DMAC7.html)
PT (1) PT1841432E (cg-RX-API-DMAC7.html)
RS (1) RS51506B (cg-RX-API-DMAC7.html)
RU (1) RU2397768C2 (cg-RX-API-DMAC7.html)
SI (1) SI1841432T1 (cg-RX-API-DMAC7.html)
UA (1) UA91204C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006059344A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200704394B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071113B2 (en) 2012-03-26 2018-09-11 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030010176A (ko) * 2001-07-25 2003-02-05 이병두 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
JP5639471B2 (ja) * 2008-07-28 2014-12-10 惠三 山口 感染症治療効果増強剤
CN101537009B (zh) * 2009-04-30 2010-09-15 海口奇力制药股份有限公司 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp 2−(1−ピペラジニル)−5−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
EP3412289A1 (en) * 2011-05-28 2018-12-12 Wockhardt Limited Antibacterial compositions
EP2768503A1 (en) * 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013042140A2 (en) * 2011-09-23 2013-03-28 Manu Chaudhary Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
EP2858636B1 (en) 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
US20150306076A1 (en) * 2012-09-27 2015-10-29 Cubist Pharmaceuticals, Inc. Tazobactam arginine antibiotic compositions
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.
EP3125887A1 (en) * 2014-03-29 2017-02-08 Wockhardt Limited Pharmaceutical compositions comprising cefepime or sulbactam
SG11201509950TA (en) * 2014-04-03 2016-01-28 Kewpie Kabushiki Kaisha Also Trading As Kewpie Corp Injection fluid bag and injection preparation
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
JP6891275B2 (ja) * 2016-11-02 2021-06-18 湘北威爾曼制薬股▲分▼有限公司Xiangbei Welman Pharmaceutical Co.,Ltd セフトリアキソンナトリウムとスルバクタムナトリウムからなる組成物
CN111249284B (zh) * 2016-11-03 2022-10-04 湘北威尔曼制药股份有限公司 治疗淋病奈瑟菌感染的头孢曲松钠舒巴坦钠
RU2665006C1 (ru) * 2017-02-28 2018-08-24 Общество с ограниченной ответственностью "Супербаг Солюшенс" Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения
EP4272831A3 (en) 2018-08-09 2024-02-21 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP4262860A4 (en) 2020-12-17 2025-11-12 Idexx Lab Inc DETECTION AND TREATMENT OF ROCKY MOUNTAIN SPRINKLE FEVER
WO2025165991A1 (en) * 2024-01-31 2025-08-07 The Penn State Research Foundation Biopolymeric anti-antibiotics and methods for making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630510B1 (en) * 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
PL1468697T3 (pl) * 2003-04-14 2008-05-30 Wyeth Corp Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071113B2 (en) 2012-03-26 2018-09-11 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
US10632139B2 (en) 2012-03-26 2020-04-28 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
US11166974B2 (en) 2012-03-26 2021-11-09 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising Diquafosol

Also Published As

Publication number Publication date
DE602005022939D1 (de) 2010-09-23
RU2007124325A (ru) 2009-01-10
WO2006059344A1 (en) 2006-06-08
KR20090101514A (ko) 2009-09-28
ZA200704394B (en) 2008-09-25
US8273732B2 (en) 2012-09-25
PT1841432E (pt) 2010-10-25
JP2008521884A (ja) 2008-06-26
HRP20100591T1 (hr) 2010-12-31
SI1841432T1 (sl) 2011-02-28
WO2006059344B1 (en) 2006-11-02
EP1841432A1 (en) 2007-10-10
CN101060846A (zh) 2007-10-24
US9012442B2 (en) 2015-04-21
DK1841432T3 (da) 2010-12-06
BRPI0517128A (pt) 2008-09-30
RU2397768C2 (ru) 2010-08-27
ES2349301T3 (es) 2010-12-29
EP1841432B1 (en) 2010-08-11
US20100160277A1 (en) 2010-06-24
PL1841432T3 (pl) 2011-01-31
KR101244362B1 (ko) 2013-03-18
JP5269415B2 (ja) 2013-08-21
NZ555075A (en) 2011-02-25
UA91204C2 (ru) 2010-07-12
US20130023512A1 (en) 2013-01-24
AU2005310888A1 (en) 2006-06-08
RS51506B (sr) 2011-06-30
CY1110886T1 (el) 2015-06-10
ATE476981T1 (de) 2010-08-15
AU2005310888B2 (en) 2011-01-06
MX2007006540A (es) 2008-01-31

Similar Documents

Publication Publication Date Title
KR101244362B1 (ko) 주사제에 유용한 베타-락타마제 억제제를 이용한 베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물
US20200093814A1 (en) Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains
CN103648496B (zh) 包含β-内酰胺抗生素、舒巴坦和β-内酰胺酶抑制剂的药物组合物
WO2013184845A1 (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2013308128B2 (en) Antibacterial compositions
US20080227732A1 (en) Treatment and Control of Severe Infections Including Cystic Fibrosis
RU2521391C2 (ru) Новые однократные единичные составы карбапенема и аминогликозида
CN1582942A (zh) 头孢呋辛钠复方制剂

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20070507

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080725

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090107

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090701

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090107

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20080725

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20090803

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090701

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20101230

Appeal identifier: 2009101007258

Request date: 20090803

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090902

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20090902

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20090803

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090311

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20080925

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090803

Effective date: 20101230

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20101231

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20090803

Decision date: 20101230

Appeal identifier: 2009101007258

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20101231

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20111021

Appeal identifier: 2011201002060

Request date: 20110304

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20111111

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20111111

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2009101007258

Request date: 20090803

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20101230

WITB Written withdrawal of application
J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20110304

Effective date: 20111021

PJ1302 Judgment (patent court)

Patent event date: 20111122

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20110304

Decision date: 20111021

Appeal identifier: 2011201002060

Appeal kind category: Appeal against decision to decline refusal